Eikon Therapeutics

EIKN Lead: Phase 2 3 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-30

Catalyst timeline

EIK1001 Ph2 topline2H 2026EIK1001 Ph2 topline, 2H 2026, major
EIK1004 readout2H 2026EIK1004 readout, 2H 2026, notable
EIK1006 IND filingEnd of 2026EIK1006 IND filing, End of 2026, notable
EIK1001 interimOct 2026EIK1001 interim, Oct 2026, major
EIK1003 Ph1 readoutOct 2026EIK1003 Ph1 readout, Oct 2026, notable
EIK1005 Ph1 readoutOct 23, 2026EIK1005 Ph1 readout, Oct 23, 2026, notable
TeLuRide-005 NSCLC readoutOct 26, 2026TeLuRide-005 NSCLC readout, Oct 26, 2026, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (13 active programs)

EIK1001

Small Molecule Target: TLR7, TLR8

Melanoma Phase 2 Phase 2/3 trial intravenous Seven and Eight Biotherapeutics NCT06697301
Non-Small Cell Lung Cancer Phase 2 Phase 2/3 trial intravenous Seven and Eight Biotherapeutics NCT06246110

IMP1734

IMP17134 · EIK1003

Small Molecule Target: PARP1

Ovarian Cancer Phase 1 Phase 1/2 trial Impact Therapeutics (Shanghai)
Breast Cancer Phase 1 Phase 1/2 trial Impact Therapeutics (Shanghai)
Prostate Cancer Phase 1 Impact Therapeutics (Shanghai)
Pancreatic Cancer Phase 1 Phase 1/2 trial Impact Therapeutics (Shanghai)

IMP1707

IMP17307 · EIK1004

Small Molecule Target: PARP1

Ovarian Cancer Phase 1 Phase 1/2 trial Impact Therapeutics (Shanghai)
Breast Cancer Phase 1 Phase 1/2 trial Impact Therapeutics (Shanghai)
Prostate Cancer Phase 1 Phase 1/2 trial Impact Therapeutics (Shanghai)
Pancreatic Cancer Phase 1 Phase 1/2 trial Impact Therapeutics (Shanghai)

EIK1004

Small Molecule Target: PARP1

Brain Metastases Phase 1 Impact Therapeutics (Shanghai)

EIK1005

Small Molecule Target: WRN

Undisclosed indication Phase 1 Phase 1/2 trial oral NCT07262619

EIK1006

Small Molecule Target: AR

Undisclosed indication Preclinical

Technology platforms

SMT

Single molecule tracking platform integrating custom-engineered super-resolution microscopy, bespoke automation, advanced data science ML/AI tools, and petabyte-scale data processing. Used to identify and validate novel targets, elucidate mechanisms of action, and accelerate drug candidate identification. Focus areas: oncology and neurologic disease.

Biotech Distilled coverage (3)

2026-08-14 UPDATE: Eikon Therapeutics (EIKN) - The Dispute Quietly Died, the Burn Did Not 🔒 Paid
2026-08-12 UPDATE: Eikon Therapeutics (EIKN) - The DMC Picked the Low Dose 🔒 Paid
2026-08-05 Eikon Therapeutics (EIKN) — Scientific Deep Dive for EIK1001, EIK1003, and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.